Figure 1.

miR‐206 was dramatically down‐regulated and negatively correlated with IL‐6 in IL‐6‐induced gefitinib‐resistant EGFR‐mutant lung carcinoma. A, relative miR‐206 expression in gefitinib‐resistant patients and healthy participants. B, the levels of serum IL‐6 in gefitinib‐resistant patients and healthy participants. C, the association of miR‐206 expression and serum IL‐6 levels was determined by Spearman's correlation. D, IC₅₀ of gefitinib in IL‐6‐treated EGFR‐mutant lung cancer cells. E, relative miR‐206 expression in IL‐6‐treated EGFR‐mutant lung cancer cells. F, the levels of IL‐6 mRNA in miR‐206‐treated EGFR‐mutant lung cancer cells. The min to max values and mean ± SD values are shown. *P < .05, **P < .01, ***P < .001